Cosette Pharmaceuticals will acquire all outstanding shares of Australia-based women’s health and dermatology company Mayne Pharma Group for a total consideration of approximately $430 million.
The combination will create a leading women’s health and dermatology focused pharmaceuticals company in the U.S. with an established presence in international markets, utilizing the strengths of two industry players to drive innovation and expand access to women’s health therapies.
The combined company will have two state-of-the-art FDA-approved manufacturing sites — one in Lincolnton, North Carolina and one in Salisbury, South Australia.
Mayne Pharma offers a portfolio of branded and generic drugs, with distribution throughout the U.S., including women’s multivitamin capsules, Bijuva capsules for menopause symptoms, and Nextstellis birth control pills.
The boards of directors of both companies have approved the transaction and Mayne’s board has unanimously recommended that its shareholders vote in favor of the transaction. The deal is expected to close in the second quarter of 2025.